clinical trials

The Takeaway: Pfizer Alzheimer’s Drug Fails Late-Stage Study

Posted on 07/24/2012 by | Brooklyn, NY | Comments

Bulletin Today | Personal HealthAn experimental treatment for Alzheimer’s disease has turned out to be a disappointment in the first finished late-stage study, manufacturer Pfizer said Monday. Called bapineuzumab, it’s one of three Alzheimer’s treatments currently in clinical trials that some have been calling our “last hope” for drugs that slow the progression of the disease.